Critical Path Institute

Critical Path Institute Appoints Dr. Klaus Romero as New CEO and Promotes Cécile Ollivier to Vice President of Global Affairs

Retrieved on: 
Thursday, January 25, 2024

AMSTERDAM, Jan. 25, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) has named Klaus Romero, M.D., M.S., FCP, as its new Chief Executive Officer and promoted Cécile Ollivier, M.S., from Managing Director, Europe to Vice President of Global Affairs.

Key Points: 
  • AMSTERDAM, Jan. 25, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) has named Klaus Romero, M.D., M.S., FCP, as its new Chief Executive Officer and promoted Cécile Ollivier, M.S., from Managing Director, Europe to Vice President of Global Affairs.
  • We are confident in his capacity to propel the organization forward in its next phase of global impact and pioneering innovation."
  • "Assuming the position of CEO at C-Path represents a profound honor, coupled with a tremendous sense of responsibility," said Romero.
  • "We are thrilled to announce the promotion of Cécile Ollivier to Vice President of Global Affairs," said C-Path Board member Tomas Salmonson Ph.D., M.S.

Patient, Research and Industry Leaders Propose Biological Definition and First Biological Staging for Parkinson's Disease

Retrieved on: 
Tuesday, January 23, 2024

The new research framework stands to accelerate and increase the success of scientific discovery and therapeutic development at all stages of Parkinson's.

Key Points: 
  • The new research framework stands to accelerate and increase the success of scientific discovery and therapeutic development at all stages of Parkinson's.
  • And ultimately, a treatment that targets the biology of the disease — rather than just its symptoms — is the way to reach a cure.
  • (A similar biological framework in Alzheimer's disease resulted in successful trials and new drug approvals, with the first drugs to slow Alzheimer's-related cognitive decline appearing in 2022 and 2023.)
  • This landmark step forward was made possible by the breakthrough discovery of a test — validated in April 2023 by The Michael J.

Patient, Research and Industry Leaders Propose Biological Definition and First Biological Staging for Parkinson's Disease

Retrieved on: 
Tuesday, January 23, 2024

The new research framework stands to accelerate and increase the success of scientific discovery and therapeutic development at all stages of Parkinson's.

Key Points: 
  • The new research framework stands to accelerate and increase the success of scientific discovery and therapeutic development at all stages of Parkinson's.
  • And ultimately, a treatment that targets the biology of the disease — rather than just its symptoms — is the way to reach a cure.
  • (A similar biological framework in Alzheimer's disease resulted in successful trials and new drug approvals, with the first drugs to slow Alzheimer's-related cognitive decline appearing in 2022 and 2023.)
  • This landmark step forward was made possible by the breakthrough discovery of a test — validated in April 2023 by The Michael J.

C-Path Appoints Dr. Klaus Romero as New CEO

Retrieved on: 
Tuesday, January 9, 2024

TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer. Romero, a seasoned clinician scientist, has been vital in positioning C-Path as an essential partner in accelerating drug development worldwide, significantly shaping scientific and regulatory pathways to expedite the delivery of therapies for people in urgent need.

Key Points: 
  • TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.
  • "Assuming the position of CEO at C-Path represents a profound honor, coupled with a tremendous sense of responsibility," said Romero.
  • His ascension to CEO is a significant milestone in our mission to bring transformative therapies to patients who desperately need them."
  • Romero will continue to serve a dual role as CEO and CSO until the CSO position is filled.

National Organization for Rare Disorders Launches Education Series to Advance Patient Involvement in Rare Disease Drug Development

Retrieved on: 
Monday, October 16, 2023

WASHINGTON, Oct. 16, 2023 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) launched a new education series in English and Spanish titled, "Rare Disease Drug Development: What Patients and Advocates Need to Know," designed to help patients and patient advocacy groups understand the drug development process.

Key Points: 
  • WASHINGTON, Oct. 16, 2023 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) launched a new education series in English and Spanish titled, "Rare Disease Drug Development: What Patients and Advocates Need to Know," designed to help patients and patient advocacy groups understand the drug development process.
  • New education series in English and Spanish: "Rare Disease Drug Development: What Patients and Advocates Need to Know.
  • "The goal of this educational series is to engage the rare disease community on their essential role in the drug development process and ultimately help produce more and better treatments for rare disease," said Rebecca Aune, Director of Education Programs at the National Organization for Rare Disorders.
  • The first modules, on "Drug Development Process", "Stakeholder Roles in Drug Development" and "Natural History Studies," are now available for free at learn.rarediseases.org .

Rett Syndrome Research Trust's Genetic Medicines Summit Sets the Stage for Accelerated Therapeutic Development

Retrieved on: 
Wednesday, October 11, 2023

TRUMBULL, Conn., Oct. 11, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts. This landmark event gathered distinguished scientists, clinicians, regulatory experts, and over 40 leading biopharma companies. The goal of the Summit was to foster dialogue among scientific, clinical, industry, and regulatory stakeholders to facilitate collaboration, identify best practices, and refine expectations to expedite pre-clinical and clinical development programs focused on genetic medicines for children and adults with Rett syndrome.

Key Points: 
  • The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts.
  • TRUMBULL, Conn., Oct. 11, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts.
  • RSRT's Rett Syndrome Genetic Medicines Summit underscores the organization's unwavering commitment to curing Rett syndrome.
  • RSRT remains steadfast in its mission to accelerate the development of genetic therapies and ultimately find a cure for Rett syndrome.

C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

Retrieved on: 
Tuesday, July 18, 2023

This integration will enable C-Path to increase its activity in Europe and broaden its global operations.

Key Points: 
  • This integration will enable C-Path to increase its activity in Europe and broaden its global operations.
  • "We are thrilled to bring the talented European teams together as a unified organisation.
  • Doing so allows us to expand our presence in Europe and strengthen our global operations.
  • With this strengthened global presence, it remains committed to leading collaborations that accelerate drug development, advancing better treatments for people worldwide.

Multistakeholder Collaborations are Vital to Advancing Technologies in Parkinson's

Retrieved on: 
Thursday, July 6, 2023

These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson's.

Key Points: 
  • These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson's.
  • Research leaders at CHeT have joined forces with organizations and regulators through C-Path's Critical Path for Parkinson's (CPP) Consortium , a precompetitive public-private partnership.
  • The goal is to enable efficient, data-driven, and patient-centric utilization of digital health technologies to speed therapeutic development," said Adams.
  • Their advancement expedites trials, enhances intelligence, reduces costs, and ultimately accelerates the delivery of new therapies and technologies to patients."

C-Path Europe: A Global Vision of Success

Retrieved on: 
Wednesday, April 26, 2023

"We are pleased with the progress and continued development of our global efforts in the regulatory and data science spaces," said C-Path Europe's Managing Director Cécile Ollivier, M.S.

Key Points: 
  • "We are pleased with the progress and continued development of our global efforts in the regulatory and data science spaces," said C-Path Europe's Managing Director Cécile Ollivier, M.S.
  • C-Path has always been committed to delivering the greatest opportunities for rapid improvement and global public health benefits.
  • It is NNRD's largest data transfer to date and the first time C-Path has received UK EPR data.
  • C-Path looks forward to continued partnerships and global efforts to fulfill its mission of accelerating the path to a healthier world.

Breaking Down Barriers in Support of Patients with Rare Diseases, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 1, 2023

TORONTO, Feb. 1, 2023 /PRNewswire-PRWeb/ -- There are over 7,000 rare diseases, and one in 10 individuals worldwide have a rare disease. Over 675 diseases have some research and development targeting supportive care, treatment or a cure for these patients, with approximately only 5% of indications having a treatment available. There is tremendous opportunity and an even larger patient need.

Key Points: 
  • The featured speakers will discuss early scientific networking in a rare disease study by partnering with patient advocacy groups.
  • The speakers will share insights about engagement and retention of patients in clinical trials, expanded access programs and patient registries.
  • The speakers will also discuss Labcorp's strategy to overcome critical barriers with innovative solutions to efficiently conduct rare disease studies.
  • Ways to successfully collaborate with patients, families and advocacy groups
    Register to learn about breaking down barriers in support of patients with rare diseases.